{"id":"percutaneous-sirolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus (rapamycin) is an mTOR inhibitor that blocks T-cell and B-cell proliferation by preventing progression through the cell cycle. When delivered percutaneously, it achieves local immunosuppressive effects at the site of application while minimizing systemic exposure. This mechanism makes it suitable for localized inflammatory or proliferative skin conditions.","oneSentence":"Percutaneous sirolimus is a topical formulation of the immunosuppressant sirolimus delivered through the skin to inhibit mTOR signaling and suppress immune cell proliferation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:33:47.763Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Percutaneous delivery for localized skin conditions (specific indication not definitively established in public literature)"}]},"trialDetails":[{"nctId":"NCT07326735","phase":"PHASE4","title":"MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon","status":"COMPLETED","sponsor":"Frisch Medical Device Private Limited","startDate":"2023-01-11","conditions":"Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))","enrollment":360},{"nctId":"NCT06863155","phase":"","title":"Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2025-05-06","conditions":"Coronary Artery Disease, Ischemic Heart Disease","enrollment":500},{"nctId":"NCT07144150","phase":"NA","title":"EVERO Drug-coated Balloon (DCB) Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Cook Research Incorporated","startDate":"2026-02","conditions":"Peripheral Vascular Disease, Peripheral Arterial Disease","enrollment":410},{"nctId":"NCT04390672","phase":"NA","title":"Multivessel TALENT","status":"ACTIVE_NOT_RECRUITING","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-09-22","conditions":"Coronary Artery Disease, Myocardial Ischemia, Coronary Disease","enrollment":1550},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT04899141","phase":"","title":"Prospective Registry of ihtDEStiny® Coronary Stent in Regular PCI Practice","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación EPIC","startDate":"2021-10-29","conditions":"Coronary Artery Disease, Ischemic Heart Disease","enrollment":400},{"nctId":"NCT07022587","phase":"NA","title":"Bioresorbable Sirolimus-eluting scaffold in de Novo Coronary Artery Lesions","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-12-20","conditions":"De Novo Stenosis, Coronary Artery Disease","enrollment":2000},{"nctId":"NCT06071429","phase":"NA","title":"Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease","status":"RECRUITING","sponsor":"R3 Vascular Inc.","startDate":"2025-04-11","conditions":"Chronic Limb-Threatening Ischemia","enrollment":300},{"nctId":"NCT06710210","phase":"NA","title":"Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Geneva","startDate":"2026-01-01","conditions":"Coronary Artery Disease, Diffuse Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)","enrollment":150},{"nctId":"NCT06214819","phase":"NA","title":"Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación EPIC","startDate":"2024-03-20","conditions":"Coronary Artery Disease","enrollment":40},{"nctId":"NCT06122974","phase":"NA","title":"Drug Eluting Temporary Spur Stent System vs Percutaneous Balloon Angioplasty for the Treatment of Critical Limb Ischemia","status":"NOT_YET_RECRUITING","sponsor":"ReFlow Medical, Inc.","startDate":"2026-08","conditions":"Critical Limb Ischemia","enrollment":518},{"nctId":"NCT03027856","phase":"NA","title":"The BIFSORB Pilot Study II","status":"COMPLETED","sponsor":"Aarhus University Hospital Skejby","startDate":"2016-09","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT04772300","phase":"NA","title":"Trial to Assess the Safety and Efficacy of Sirolimus-Coated Balloon vs. Uncoated Standard Angioplasty for the Treatment of Below-the-knee Peripheral Arterial Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jena University Hospital","startDate":"2022-02-10","conditions":"Peripheral Artery Disease","enrollment":230},{"nctId":"NCT04475783","phase":"NA","title":"Sirolimus- vs. Paclitaxel-Drug Coated Ballons in Patients With Peripheral Artery Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jena University Hospital","startDate":"2021-04-13","conditions":"Peripheral Artery Disease","enrollment":478},{"nctId":"NCT05556681","phase":"NA","title":"Study of BD Sirolimus Drug Coated Catheter for Treatment of Femoropopliteal Arteries","status":"COMPLETED","sponsor":"C. R. Bard","startDate":"2022-08-02","conditions":"Peripheral Arterial Disease, Peripheral Artery Disease, Stenosis Artery","enrollment":34},{"nctId":"NCT04280029","phase":"NA","title":"SELUTION SLR™ 014 In-stent Restenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.A. Med Alliance S.A.","startDate":"2020-07-06","conditions":"Coronary Restenosis","enrollment":418},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT07091682","phase":"NA","title":"Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions","status":"RECRUITING","sponsor":"Biotronik AG","startDate":"2025-02-18","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery, Myocardial Ischemia","enrollment":100},{"nctId":"NCT07045194","phase":"NA","title":"Virtue® SAB in the Treatment of Coronary ISR Trial","status":"RECRUITING","sponsor":"Orchestra BioMed, Inc","startDate":"2025-10-20","conditions":"Coronary Artery Disease","enrollment":740},{"nctId":"NCT06168305","phase":"","title":"Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Genoss Co., Ltd.","startDate":"2023-11-15","conditions":"Percutaneous Coronary Intervention, Multivessel Coronary Artery Disease","enrollment":1000},{"nctId":"NCT05946629","phase":"NA","title":"SELUTION 4 De Novo Small Vessel IDE Trial","status":"RECRUITING","sponsor":"M.A. Med Alliance S.A.","startDate":"2023-10-20","conditions":"Coronary Artery Disease","enrollment":960},{"nctId":"NCT06822712","phase":"NA","title":"Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for De Novo Coronary Bifurcation Lesions","status":"RECRUITING","sponsor":"BrosMed Medical Co., Ltd","startDate":"2025-03-03","conditions":"Coronary Arterial Disease (CAD)","enrollment":250},{"nctId":"NCT03508219","phase":"NA","title":"POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)","status":"TERMINATED","sponsor":"ECRI bv","startDate":"2018-08-10","conditions":"Coronary Stenosis","enrollment":130},{"nctId":"NCT06065345","phase":"NA","title":"BRight Pharmacokinetic Study","status":"COMPLETED","sponsor":"Biotronik CRC Inc.","startDate":"2024-05-01","conditions":"Peripheral Artery Disease","enrollment":6},{"nctId":"NCT06866756","phase":"","title":"Experience in Percutaneous Coronary Intervention With Sirolimus Drug-Coated Balloon and Paclitaxel Drug-Coated Balloon","status":"RECRUITING","sponsor":"Andres Iñiguez Romo","startDate":"2021-09-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":479},{"nctId":"NCT04612179","phase":"","title":"Post-Market Registry to Evaluate the Safety and Efficacy of the The SUPRAFLEX CRUZ™ Sirolimus Eluting Coronary Stent System in the Treatment of an Octo- and Nonagenerian All-Comer Patient Cohort With Coronary Artery Disease - the Cruz Senior Study","status":"COMPLETED","sponsor":"IHF GmbH - Institut für Herzinfarktforschung","startDate":"2021-06-23","conditions":"Coronary Disease","enrollment":2017},{"nctId":"NCT07004569","phase":"","title":"Angiolite Registry Study","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-05-28","conditions":"With Left Main Coronary Artery Lesions","enrollment":55},{"nctId":"NCT05705973","phase":"","title":"Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Terumo Europe N.V.","startDate":"2023-04-25","conditions":"Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease","enrollment":3000},{"nctId":"NCT05066789","phase":"PHASE4","title":"CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2022-01-17","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT06914089","phase":"NA","title":"Thin Versus Thicker Strut Thickness Stents in Primary Percutaneous Intervention","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-10-01","conditions":"Primary Percutaneous Coronary Intervention","enrollment":146},{"nctId":"NCT05406622","phase":"NA","title":"MOTIV BTK Randomized Controlled Trial","status":"RECRUITING","sponsor":"REVA Medical, Inc.","startDate":"2022-06-10","conditions":"Critical Limb Ischemia","enrollment":292},{"nctId":"NCT05692882","phase":"NA","title":"A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China","status":"RECRUITING","sponsor":"Sino Medical Sciences Technology Inc.","startDate":"2023-11-16","conditions":"Intracranial Arteriosclerosis, Stenosis Artery, Drug-Eluting Stents","enrollment":1000},{"nctId":"NCT04192747","phase":"NA","title":"The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elixir Medical Corporation","startDate":"2020-12-16","conditions":"Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease","enrollment":445},{"nctId":"NCT05663944","phase":"PHASE2","title":"REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2022-07-25","conditions":"Advanced Chronic Liver Disease","enrollment":41},{"nctId":"NCT05033964","phase":"PHASE2","title":"The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elixir Medical Corporation","startDate":"2021-12-15","conditions":"Coronary Artery Disease","enrollment":200},{"nctId":"NCT06420505","phase":"","title":"Evaluation of the Vivo Isar Stent System in Routine Clinical Practice","status":"RECRUITING","sponsor":"Translumina GmbH","startDate":"2023-11-29","conditions":"Artery Coronary Stenosis","enrollment":3000},{"nctId":"NCT04525794","phase":"NA","title":"BRight DCB First-in-Human Study","status":"COMPLETED","sponsor":"Biotronik CRC Inc.","startDate":"2021-02-04","conditions":"Peripheral Artery Disease","enrollment":48},{"nctId":"NCT05362994","phase":"NA","title":"Selution Sirolimus-eluting Balloon for Internal Pudendal-penile Artery Disease-related Erectile Dysfunction","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2022-09-19","conditions":"Erectile Dysfunction, Peripheral Arterial Disease, Arterial Stenosis","enrollment":54},{"nctId":"NCT06345209","phase":"NA","title":"Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for Coronary Small Vessels","status":"NOT_YET_RECRUITING","sponsor":"BrosMed Medical Co., Ltd","startDate":"2024-05","conditions":"Coronary Artery Disease","enrollment":236},{"nctId":"NCT04561739","phase":"NA","title":"Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital","startDate":"2021-02-01","conditions":"De Novo Stenosis, Coronary Artery Disease","enrollment":2272},{"nctId":"NCT04921722","phase":"PHASE4","title":"Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2021-10-22","conditions":"Kaposiform Hemangioendothelioma, Tufted Angioma, Superficial Vascular Anomalies","enrollment":75},{"nctId":"NCT02870985","phase":"NA","title":"BIOTRONIK Orsiro Pre-Marketing Registration","status":"COMPLETED","sponsor":"Biotronik (Beijing) Medical Device Ltd.","startDate":"2015-07-14","conditions":"Coronary Artery Disease","enrollment":440},{"nctId":"NCT04135989","phase":"PHASE4","title":"Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2020-01-01","conditions":"Coronary Artery Disease, Acute Coronary Syndrome, Chronic Coronary Syndrome","enrollment":2106},{"nctId":"NCT04660240","phase":"NA","title":"Randomized Trial Comparing Two Sirolimus-Eluting Stents in Diabetes Mellitus","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2020-10-01","conditions":"Diabetes Mellitus, Coronary Artery Disease, Acute Coronary Syndrome","enrollment":860},{"nctId":"NCT03600961","phase":"","title":"BIOFLOW-SV Portugal Registry","status":"TERMINATED","sponsor":"Biotronik AG","startDate":"2018-07-05","conditions":"Ischemic Heart Disease","enrollment":173},{"nctId":"NCT03600948","phase":"","title":"BIOFLOW-SV All Comers Registry","status":"TERMINATED","sponsor":"Biotronik AG","startDate":"2018-08-27","conditions":"de Novo, Symptomatic Ischemic Heart Disease, Restenoses, Coronary","enrollment":261},{"nctId":"NCT04107298","phase":"NA","title":"Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon","status":"COMPLETED","sponsor":"SurModics, Inc.","startDate":"2020-06-29","conditions":"Peripheral Arterial Disease, Critical Lower Limb Ischemia","enrollment":35},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT05731687","phase":"NA","title":"Bifurcation PCI With a Hybrid Strategy With Drug Eluting Balloons Versus a Stepwise Provisional Two-stent Strategy","status":"RECRUITING","sponsor":"Cathreine BV","startDate":"2023-03-21","conditions":"Coronary Artery Disease, Coronary Bifurcation Lesion","enrollment":500},{"nctId":"NCT05450042","phase":"NA","title":"Vascular Effects Through Sirolimus vs. Paclitaxel DCB Implantation","status":"UNKNOWN","sponsor":"University Hospital, Essen","startDate":"2022-04-06","conditions":"Peripheral Arterial Disease, Flow-mediated Dilation, Drug Eluting Balloon","enrollment":70},{"nctId":"NCT03216733","phase":"NA","title":"SORT OUT X - Combo Stent Versus ORSIRO Stent","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital Skejby","startDate":"2017-06-01","conditions":"Coronary Heart Disease, Angina Pectoris, Myocardial Infarction","enrollment":3148},{"nctId":"NCT04923191","phase":"NA","title":"The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent","status":"RECRUITING","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2021-11-12","conditions":"Coronary Artery Disease","enrollment":2540},{"nctId":"NCT05963620","phase":"","title":"Long-term Follow-up of a Randomized Comparison of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Surgery","status":"UNKNOWN","sponsor":"Heart Center Leipzig - University Hospital","startDate":"2023-01-01","conditions":"Coronary Stenosis, Coronary Artery Disease","enrollment":201},{"nctId":"NCT02385279","phase":"NA","title":"Study Comparing the MiStent SES Versus the XIENCE EES Stent","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2015-03-20","conditions":"Coronary Stenosis","enrollment":1398},{"nctId":"NCT03952273","phase":"NA","title":"Sort Out XI - Combo Stent Versus BioMatrix Alpha Stent","status":"ACTIVE_NOT_RECRUITING","sponsor":"Phillip Freeman","startDate":"2019-08-14","conditions":"Coronary Artery Disease","enrollment":3141},{"nctId":"NCT05780359","phase":"NA","title":"Evaluating the Safety and Efficacy of the G-stream® Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery","status":"RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2022-05-27","conditions":"Peripheral Artery Disease","enrollment":280},{"nctId":"NCT03045913","phase":"","title":"Genoss DES Prospective Multicenter Registry","status":"COMPLETED","sponsor":"Young Jin Youn, MD, PhD","startDate":"2016-11-18","conditions":"Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction","enrollment":2000},{"nctId":"NCT05662618","phase":"NA","title":"To Verify the Efficacy and Safety of Rapamycin Coated Peripheral Balloon Catheter in the Treatment of Femoral Popliteal Artery Disease","status":"UNKNOWN","sponsor":"Shanghai Bomaian Medical Technology Co., Ltd","startDate":"2022-12-31","conditions":"Peripheral Arterial Disease","enrollment":276},{"nctId":"NCT03621501","phase":"NA","title":"Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2018-06-22","conditions":"Acute Coronary Syndrome","enrollment":1525},{"nctId":"NCT03399994","phase":"NA","title":"Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES","status":"COMPLETED","sponsor":"Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS","startDate":"2018-05-21","conditions":"Coronary Artery Disease, Diabetes","enrollment":137},{"nctId":"NCT04157153","phase":"NA","title":"First in Men Study: BIOMAG-I","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotronik AG","startDate":"2020-04-27","conditions":"Coronary Artery Disease","enrollment":116},{"nctId":"NCT05444452","phase":"NA","title":"GENOSS Coronary Stent Clinical Trial","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2022-04-24","conditions":"Ischemic Heart Disease","enrollment":850},{"nctId":"NCT04014595","phase":"","title":"PREPARE-CALC-COMBO: Severely Calcified Coronary Lesions Prepared With Rotational Atherectomy and Modified Balloons","status":"UNKNOWN","sponsor":"Segeberger Kliniken GmbH","startDate":"2019-01-01","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT02073565","phase":"NA","title":"HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt","status":"COMPLETED","sponsor":"OrbusNeich","startDate":"2014-02","conditions":"Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":572},{"nctId":"NCT02240407","phase":"PHASE1","title":"Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-10-17","conditions":"Pompe Disease","enrollment":2},{"nctId":"NCT05294822","phase":"NA","title":"Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-09-30","conditions":"Diabetes","enrollment":20},{"nctId":"NCT04849325","phase":"NA","title":"IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease","status":"UNKNOWN","sponsor":"Biotyx Medical (Shenzhen) Co., Ltd.","startDate":"2021-12-09","conditions":"Critical Limb Ischemia (CLI)","enrollment":120},{"nctId":"NCT04885816","phase":"NA","title":"Drug-eluting Balloon Versus Drug-eluting Stent for High Bleeding Risk Angioplasty","status":"TERMINATED","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2021-04-20","conditions":"High Bleeding Risk, Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI)","enrollment":5},{"nctId":"NCT04896177","phase":"NA","title":"Sirolimus DEB in Coronary Bifurcation Lesions","status":"RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-03-18","conditions":"Coronary Bifurcation Lesions","enrollment":280},{"nctId":"NCT04179045","phase":"NA","title":"A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Bio-heart Biological Technology Co., Ltd.","startDate":"2021-03-01","conditions":"Coronary Artery Disease","enrollment":785},{"nctId":"NCT02870140","phase":"NA","title":"Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2016-10-21","conditions":"Coronary Stenosis","enrollment":1435},{"nctId":"NCT04591938","phase":"NA","title":"FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study","status":"UNKNOWN","sponsor":"Joost Daemen","startDate":"2019-10-01","conditions":"Percutaneous Coronary Intervention, Myocardial Revascularization, Tomography, Optical Coherence","enrollment":50},{"nctId":"NCT00152308","phase":"PHASE4","title":"Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis","status":"TERMINATED","sponsor":"Translumina GmbH","startDate":"2004-12","conditions":"Coronary Disease","enrollment":333},{"nctId":"NCT01879358","phase":"NA","title":"Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2012-11","conditions":"Coronary Artery Disease, Ischemic Heart Disease","enrollment":2314},{"nctId":"NCT02623140","phase":"PHASE4","title":"BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2015-12","conditions":"Ischaemic Heart Disease","enrollment":3150},{"nctId":"NCT02972671","phase":"NA","title":"Trial of MiStent Compared to Xience in Japan","status":"UNKNOWN","sponsor":"Micell Technologies","startDate":"2016-11-28","conditions":"Coronary (Artery); Disease","enrollment":120},{"nctId":"NCT02579031","phase":"NA","title":"A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2016-04","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":1300},{"nctId":"NCT03716102","phase":"NA","title":"OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Svelte Medical Systems, Inc.","startDate":"2018-11-21","conditions":"Acute Coronary Syndrome","enrollment":12},{"nctId":"NCT03871127","phase":"","title":"Ten-Year Outcomes of PRE-COMBAT Trial","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2019-05-01","conditions":"Coronary Artery Disease","enrollment":600},{"nctId":"NCT03234348","phase":"PHASE3","title":"MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2017-07-01","conditions":"Acute Coronary Syndrome, ST Segment Elevation Myocardial Infarction, Stent","enrollment":151},{"nctId":"NCT02502851","phase":"NA","title":"The Comparison of Strategies to PREPARE Severely CALCified Coronary Lesions Trial (PREPARE-CALC)","status":"COMPLETED","sponsor":"Segeberger Kliniken GmbH","startDate":"2014-09","conditions":"Coronary Atherosclerosis Due to Severely Calcified Coronary Lesion","enrollment":200},{"nctId":"NCT02127138","phase":"NA","title":"The Study of Active Transfer of Plaque Technique for Unprotected Distal Left Main Bifurcation Lesions","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2015-05","conditions":"Coronary Heart Disease","enrollment":316},{"nctId":"NCT03284255","phase":"NA","title":"Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Bio-heart Biological Technology Co., Ltd.","startDate":"2017-09-11","conditions":"Coronary Artery Disease, Antineoplastic Agents","enrollment":431},{"nctId":"NCT02941224","phase":"PHASE1","title":"First-in-human Evaluation of the SELUTION DCB, a Novel Sirolimus Coated Balloon in Peripheral Arteries","status":"COMPLETED","sponsor":"M.A. Med Alliance S.A.","startDate":"2016-10","conditions":"Patients With Peripheral Artery Disease in the SFA or PA","enrollment":50},{"nctId":"NCT04150016","phase":"NA","title":"In-stent Repair and Vessel Reaction of STEMI Patients With OCT","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-03-08","conditions":"Drug-eluting Stents, Percutaneous Coronary Intervention, Optical Coherence Tomography","enrollment":44},{"nctId":"NCT02688829","phase":"NA","title":"The First-In-Man Pilot Study of Firehawk","status":"COMPLETED","sponsor":"Shanghai MicroPort Medical (Group) Co., Ltd.","startDate":"2009-12","conditions":"Coronary Heart Disease","enrollment":21},{"nctId":"NCT03484234","phase":"NA","title":"Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)","status":"TERMINATED","sponsor":"Seung-Jung Park","startDate":"2018-07-27","conditions":"Coronary Artery Disease, Coronary Stenosis","enrollment":36},{"nctId":"NCT03454724","phase":"NA","title":"Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.","status":"UNKNOWN","sponsor":"Meril Life Sciences Pvt. Ltd.","startDate":"2020-01-01","conditions":"Coronary Artery Disease","enrollment":484},{"nctId":"NCT00389220","phase":"NA","title":"Limus Eluted From A Durable Versus ERodable Stent Coating","status":"COMPLETED","sponsor":"Biosensors Europe SA","startDate":"2006-11","conditions":"Coronary Disease, Coronary Stenosis","enrollment":1707},{"nctId":"NCT03785431","phase":"NA","title":"Vascular Healing After Implantation of FANTOM Bioresorbable Scaffold in STEMI: A FANTOM STEMI Study","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2017-06-06","conditions":"STEMI, Cardiovascular Disease, Bioresorbable Scaffold","enrollment":20},{"nctId":"NCT01443104","phase":"NA","title":"Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2012-02","conditions":"Coronary Artery Disease, Angina Pectoris, Myocardial Infarction","enrollment":2119},{"nctId":"NCT03563989","phase":"NA","title":"STENTYS Xposition S in the Treatment of Chronic Total Artery Occlusion","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-06-26","conditions":"Chronic Total Occlusion, Coronary Artery Disease","enrollment":50},{"nctId":"NCT03548272","phase":"PHASE4","title":"BiOSS LIM C vs 2nd Generation DES in Non-LM Bifurcations","status":"UNKNOWN","sponsor":"Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland","startDate":"2018-06-12","conditions":"Coronary Artery Disease","enrollment":518},{"nctId":"NCT03509532","phase":"","title":"DRUG ELUTING STENT FOR DIABETIC PATIENTS IN CORONARY ARTERY DISEASE TREATMENT","status":"UNKNOWN","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2017-01","conditions":"Coronary Artery Disease","enrollment":5000},{"nctId":"NCT01382043","phase":"","title":"Angiographic and IVUS Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals (AIFSIDDES)","status":"COMPLETED","sponsor":"Liuhuaqiao Hospital","startDate":"2009-06","conditions":"Percutaneous Coronary Angioplasty","enrollment":48},{"nctId":"NCT02597283","phase":"NA","title":"Coronary Bifurcation Lesions Treated With Biguard Stent System","status":"WITHDRAWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2015-12","conditions":"Coronary Artery Disease","enrollment":""},{"nctId":"NCT02102997","phase":"","title":"Deutsches Dual Therapy Stent Register","status":"TERMINATED","sponsor":"OrbusNeich","startDate":"2013-07","conditions":"Coronary Artery Disease","enrollment":130},{"nctId":"NCT02916485","phase":"NA","title":"Safety and Clinical Performance of a Sirolimus-eluting Absorbable Metal Scaffold","status":"SUSPENDED","sponsor":"Biotronik AG","startDate":"2017-06","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT00977938","phase":"PHASE4","title":"The Dual Antiplatelet Therapy Study (DAPT Study)","status":"COMPLETED","sponsor":"Baim Institute for Clinical Research","startDate":"2009-10","conditions":"Coronary Artery Disease","enrollment":25682}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1736,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rapamycin"],"phase":"marketed","status":"active","brandName":"Percutaneous sirolimus","genericName":"Percutaneous sirolimus","companyName":"Children's Hospital of Fudan University","companyId":"children-s-hospital-of-fudan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Percutaneous sirolimus is a topical formulation of the immunosuppressant sirolimus delivered through the skin to inhibit mTOR signaling and suppress immune cell proliferation. Used for Percutaneous delivery for localized skin conditions (specific indication not definitively established in public literature).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}